Drug Pipeline

CAEL-101 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
0
Recruiting
2
Phase 3
2
Top Sponsors
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-05-29 NCT07615270 A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue… Early Phase 1 Not Yet Recruiting
Active Studies by Phase
Phase 3
2
Early Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT04504825 A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb… AL Amyloidosis Active, Not Recruiting
NCT04512235 A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa… AL Amyloidosis Active, Not Recruiting
Early Phase 1
NCT07615270 A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue… AL Amyloidosis Not Yet Recruiting
Sponsors Running CAEL-101 Trials
Alexion Pharmaceuticals, Inc. (2) Stanford University (1)
Disease Areas
Amyloidosis (3)
Get alerts when CAEL-101 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free